Home / Blood / C1-Inhibitor, plasma derived
ATC B06AC01 · Drugs Used in Hereditary Angioedema · updated 2 Nov 2026
C1-Inhibitor, plasma derived shortage
As of 2 Nov 2026, C1-Inhibitor, plasma derived has a reported shortage in 1 of the 16 countries we track (Czechia), covering 1 product from 1 company.
Is there a C1-Inhibitor, plasma derived shortage?
Yes. As of 2 Nov 2026, C1-Inhibitor, plasma derived is reported short in 1 of the 16 countries we track: Czechia. The earliest expected return is 31 Dec 2026 (Czechia).
Timeline
Solid bars run from the reported start to today; faded bars show the time left until the expected return. An arrow means no return date was given.
Which companies are short
products short, all countriesListed: CSL CSL · ASX
Compared with similar medicines
ATC group B06AC · Drugs Used in Hereditary AngioedemaAffected products
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| CZ | BERINERT 3000IU 3000IU INJ PSO LQF 5+5X5,6ML | CSL Behring GmbH, Marburg | 19 Aug 2025 | 31 Dec 2026 | Commercial decision or withdrawal Obchodní/marketingové důvody |
"Expected back" is the date the company gave the authority, when it gave one. Ask a pharmacist about alternatives.
Questions
Is there a C1-Inhibitor, plasma derived shortage?
Yes. As of 2 Nov 2026, C1-Inhibitor, plasma derived is reported short in 1 of the 16 countries we track: Czechia. The earliest expected return is 31 Dec 2026 (Czechia).
When will C1-Inhibitor, plasma derived be back in stock?
Companies expect supply back from 31 Dec 2026 in Czechia; Czechia: 31 Dec 2026. These are company estimates reported to each authority.
Why is C1-Inhibitor, plasma derived in short supply?
The most common reason reported is: commercial decision or withdrawal. Reasons by product are listed in the table below.
Which companies have C1-Inhibitor, plasma derived shortages?
CSL.